Health technology assessment institute NICE has recommended that Roche’s Vabysmo (faricimab) be funded via the National Health Service in England, where thousands of people with wet age-related macular degeneration (AMD) or diabetic macular edema (DME) could be eligible to receive the VEGF therapy.
By contrast, it advised that Alnylam Pharmaceuticals’ Oxlumo (lumasiran), for primary hyperoxaluria type 1 (PH1), and Vifor Pharma’s...








